Pyrazolopyridine FGFR Agonists for Receptor Dimerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective synthetic molecules that can induce Fibroblast Growth Factor Receptor (FGFR) dimerization, which is crucial for activating cellular processes like angiogenesis and tissue regeneration, as natural compounds and existing synthetic compounds fail to activate natural receptors effectively.
Innovation Solution
Development of novel pyrazolopyridine derivatives with a dimeric structure that act as FGFR agonists, capable of inducing receptor dimerization and activation by forming a covalent linkage between two monomer units via a flexible linker group, allowing contact with extracellular binding sites of FGFR transmembrane receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural compounds (FGFs, PDGF, VEGF, EPO, G-CSF, TPO, cytokines, insulin) are used to activate FGFR dimerization, then receptor activation and downstream cellular processes (angiogenesis, tissue regeneration) are achieved, but the therapeutic applicability is limited due to their natural complexity, short half-life, and inability to be effectively delivered or stored
Solution Approach 1:
The patent creates synthetic copies of natural FGFs that replicate their biological function. The compounds of formula (I) are designed to bind to and activate FGFR in the same manner as natural FGFs, achieving receptor dimerization and downstream signaling without using the complex natural proteins. This allows for stable, synthesizable molecules that mimic natural ligand behavior.
Solution Approach 2:
The invention modifies key parameters of natural FGFs by creating small-molecule analogs with different physical and chemical properties. The synthetic compounds have improved stability, longer half-life, and better pharmacokinetic profiles compared to natural FGFs, while maintaining the critical ability to induce FGFR dimerization and activate downstream pathways.
2Reliability
If FGFR dimerization is induced for therapeutic purposes (angiogenesis, tissue repair), then cellular proliferation and regeneration are activated, but existing synthetic compounds fail to effectively activate natural FGFR receptors
Solution Approach 1:
The patent segments the complex natural FGF molecule into smaller, synthetically accessible components. The compounds of formula (I) represent simplified molecular structures that retain the essential dimerization-inducing capability while being amenable to chemical synthesis and modification, thereby increasing the availability of effective synthetic agonists.
Solution Approach 2:
The invention creates composite molecular structures combining elements that facilitate FGFR binding with features that enable synthetic production and stabilization. The compounds integrate pharmacophore elements necessary for receptor interaction with structural features that improve synthetic accessibility and pharmacological properties.
3Reliability
If natural FGFs are used therapeutically, then angiogenesis and tissue regeneration are promoted, but their short half-life and instability limit their clinical utility and delivery
Solution Approach 1:
The patent replaces the expensive, unstable natural FGF proteins with inexpensive, stable synthetic small molecules that can be manufactured readily and stored long-term. These compounds serve as durable alternatives that eliminate the need for frequent administration and complex storage conditions required for natural FGFs.
Solution Approach 2:
The invention fundamentally changes the physical and chemical parameters of the therapeutic agent by transitioning from large, labile protein molecules to small, stable synthetic compounds. This results in dramatically improved half-life, stability, and pharmacokinetic properties while preserving the essential ability to activate FGFR and promote angiogenesis and tissue repair.
Data Source
AI summary
The invention relates to novel heterocyclic compounds which are pyrazolopyridine derivatives that induce fibroblast growth factor receptor (FGFR) dimerization, having the general formula: M1-L-M2 in which M1 or M2, which may be identical or different, each represent, independently of one another, a monomer unit M and L represents a linker group which links M1 and M2 covalently with the monomer unit which follows: Process for the preparation thereof and therapeutic use thereof.